News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

KAI Pharmaceuticals, Inc. Acquires Patents from Progen Pharmaceuticals Limited (PGLA), Broadening KAI's Intellectual Property Estate Covering Peptide-Based Therapies



6/30/2009 11:02:43 AM

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, announced today the acquisition of an extensive collection of issued and pending patents from Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq:PGLA), a globally focused biotechnology company. The patents claim compositions and methods related to transporter molecules that can deliver compounds, including peptides such as those being developed in the KAI pipeline, across biological membranes and into cells. Terms of the agreement were not disclosed.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES